The above publications received comments from the researchers we surveyed. Here are further 2023 publications that Michael included in his list.
***
Jones, G., Herrmann, F., & Wang, E. (2023). Associations between individual hallucinogens and hallucinogen misuse among U.S. Adults who recently initiated hallucinogen use. Addictive behaviors reports, 18, 100513. https://doi.org/10.1016/j.abrep.2023.100513
Pettorruso, M., Guidotti, R., d’Andrea, G., De Risio, L., D’Andrea, A., Chiappini, S., Carullo, R., Barlati, S., Zanardi, R., Rosso, G., De Filippis, S., Di Nicola, M., Andriola, I., Marcatili, M., Nicolò, G., Martiadis, V., Bassetti, R., Nucifora, D., De Fazio, P., Rosenblat, J. D., … REAL-ESK Study Group (2023). Predicting outcome with Intranasal Esketamine treatment: A machine-learning, three-month study in Treatment-Resistant Depression (ESK-LEARNING). Psychiatry Research, 327, 115378. https://doi.org/10.1016/j.psychres.2023.115378
Estrade, I., Petit, A. C., Sylvestre, V., Danon, M., Leroy, S., Perrain, R., Vinckier, F., Mekaoui, L., Gaillard, R., Advenier-Iakovlev, E., Mancusi, R. L., Poupon, D., De Maricourt, P., & Gorwood, P. (2023). Early effects predict trajectories of response to esketamine in treatment-resistant depression. Journal of affective disorders, 342, 166–176. https://doi.org/10.1016/j.jad.2023.09.030
Ko, K., Carter, B., Cleare, A. J., & Rucker, J. J. (2023). Predicting the Intensity of Psychedelic-Induced Mystical and Challenging Experience in a Healthy Population: An Exploratory Post-Hoc Analysis. Neuropsychiatric disease and treatment, 19, 2105–2113. https://doi.org/10.2147/NDT.S426193
Donegan, C. J., Daldegan-Bueno, D., Sumner, R., Menkes, D., Evans, W., Hoeh, N., Sundram, F., Reynolds, L., Ponton, R., Cavadino, A., Smith, T., Roop, P., Allen, N., Abeysinghe, B., Svirskis, D., Forsyth, A., Bansal, M., & Muthukumaraswamy, S. (2023). An open-label pilot trial assessing tolerability and feasibility of LSD microdosing in patients with major depressive disorder (LSDDEP1). Pilot and feasibility studies, 9(1), 169. https://doi.org/10.1186/s40814-023-01399-8
Bhuiya, N. M. A., Jacobs, R. J., Wang, K., Sun, Y., Nava, B., Sampiere, L., Yerubandi, A., & Caballero, J. (2023). Predictors of Pharmacy Students’ Attitudes About the Therapeutic Use of Psilocybin. Cureus, 15(9), e45169. https://doi.org/10.7759/cureus.45169
Walsh, C. A., Gorfinkel, L., Shmulewitz, D., Stohl, M., & Hasin, D. S. (2024). Use of Lysergic Acid Diethylamide by Major Depression Status. JAMA Psychiatry, 81(1), 89-96. Epub 2023 Oct 11. https://doi.org/10.1001/jamapsychiatry.2023.3867
Armstrong, S. B., Levin, A. W., Xin, Y., Horan, J. C., Luoma, J., Nagib, P., Pilecki, B., & Davis, A. K. (2023). Differences in attitudes and beliefs about psychedelic-assisted therapy among social workers, psychiatrists, and psychologists in the United States. Journal of Psychedelic Studies, 7(S1), 61-67. https://doi.org/10.1556/2054.2023.00245
Harrison, T. R. (2023). Altered stakes: Identifying gaps in the informed consent process for psychedelic-assisted therapy trials. Journal of Psychedelic Studies, 7(S1), 48-60. https://doi.org/10.1556/2054.2023.00267
Devenot, N. (2023). TESCREAL hallucinations: Psychedelic and AI hype as inequality engines. Journal of Psychedelic Studies, 7(S1), 22-39. https://doi.org/10.1556/2054.2023.00292
Monte, A. A., Schow, N. S., Black, J. C., Bemis, E. A., Rockhill, K. M., & Dart, R. C. (2023). The Rise of Psychedelic Drug Use Associated With Legalization/Decriminalization: An Assessment With the Nonmedical Use of Prescription Drugs Survey. Annals of Emergency Medicine. Advance online publication. https://doi.org/10.1016/j.annemergmed.2023.11.003
Friedman, S. F., & Ballentine, G. (2023). Trajectories of sentiment in 11,816 psychoactive narratives. Human Psychopharmacology Clinical and Experimental. Advance online publication. https://doi.org/10.1002/hup.2889
Beaussant, Y., Tarbi, E., Nigam, K., Miner, S., Sager, Z., Sanders, J. J., Ljuslin, M., Guérin, B., Thambi, P., Tulsky, J. A., & Agrawal, M. (2023). Acceptability of psilocybin-assisted group therapy in patients with cancer and major depressive disorder: Qualitative analysis. Cancer. Advance online publication. https://doi.org/10.1002/cncr.35024
Rocha, J. M., Reis, J. A. S., Rossi, G. N., Bouso, J. C., Hallak, J. E. C., & dos Santos, R. G. (2023). Guidelines for Establishing Safety in Ayahuasca and Ibogaine Administration in Clinical Settings. Psychoactives, 2(4), 373-386. https://doi.org/10.3390/psychoactives2040024
Orłowski, P., Hobot, J., Ruban, A., Szczypiński, J., & Bola, M. (2023). The relation between naturalistic use of psychedelics and perception of emotional stimuli: An event-related potential study comparing non-users and experienced users of classic psychedelics. Journal of Psychopharmacology. Advance online publication. https://doi.org/10.1177/02698811231216322
Marseille, E., Stauffer, C. S., Agrawal, M., Thambi, P., Roddy, K., Mithoefer, M., Bertozzi, S. M., Kahn, J. G. (2023). Group psychedelic therapy: empirical estimates of cost-savings and improved access. Frontiers in Psychiatry, 14. https://doi.org/10.3389/fpsyt.2023.1293243
Mian, M. N., Altman, B. R., Low, F., & Earleywine, M. (2023). Development of the Protective Strategies for Psychedelics Scale: A novel inventory to assess safety strategies in the context of psychedelics. Journal of Psychopharmacology. Advance online publication. https://doi.org/10.1177/02698811231214060
Nicholas, C. R., Horton, D. M., Malicki, J., Baltes, A., Hutson, P. R., & Brown, R. T. (2023). Psilocybin for Opioid Use Disorder in Two Adults Stabilized on Buprenorphine: A Technical Report on Study Modifications and Preliminary Findings. Psychedelic Medicine, 1(4), 253-261. https://doi.org/10.1089/psymed.2023.0012
Weintraub, M. J., Jeffrey, J. K., Grob, C. S., Ichinose, M. C., Bergman, R. L., Cooper, Z. D., Miklowitz, D. J. (2023). Psilocybin-Assisted Cognitive Behavioral Therapy for Adults with Major Depressive Disorder: Rationale and Treatment Development. Psychedelic Medicine, 1(4), 230-240. https://doi.org/10.1089/psymed.2023.0018
Penn, A., & Yehuda, R. (2023). Preventing the Gaps in Psychedelic Research from Becoming Practice Pitfalls: A Translational Research Agenda. Psychedelic Medicine, 1(4), 198-209. https://doi.org/10.1089/psymed.2023.0017
Harduf, A., Panishev, G., Harel, E. V., Stern, Y., & Salomon, R. (2023). The bodily self from psychosis to psychedelics. Scientific Reports, 13(1), 21209. https://doi.org/10.1038/s41598-023-47600-z
Solomon, T. M., Hajduk, M., Majernik, M., Jemison, J., Deschamps, A., Scoggins, J., Kolar, A., Pinheiro, M. A., Dubec, P., Skala, O., Muir, O., Tinkelman, A., Karlin, D. R., & Barrow, R. (2023). Evaluating passive physiological data collection during Spravato treatment. Frontiers in Digital Health, 5. https://doi.org/10.3389/fdgth.2023.1281529
Moaddel, R., Farmer, C. A., Yavi, M., Kadriu, B., Zhu, M., Fan, J., Chen, Q., Lehrmann, E., Fantoni, G., De, S., Mazucanti, C. H., Acevedo-Diaz, E. E., Yuan, P., Gould, T. D., Park, L. T., Egan, J. M., Ferrucci, L., & Zarate, C. A. (2023). Cerebrospinal fluid exploratory proteomics and ketamine metabolite pharmacokinetics in human volunteers after ketamine infusion. iScience, 26(12), 108527. https://doi.org/10.1016/j.isci.2023.108527
Jollant, F., Demattei, C., Fabbro, P., & Abbar, M. (2023). Clinical predictive factors and trajectories of suicidal remission over 6 weeks following intravenous ketamine for suicidal ideation. Journal of Affective Disorders, 347, 1-7. https://doi.org/10.1016/j.jad.2023.11.043
Wirsching, A., Bostoen, T., & Huizink, A. C. (2023). A Psychometric Evaluation of the Dutch Revised Mystical Experience Questionnaire. Journal of Psychoactive Drugs, ahead-of-print. https://doi.org/10.1080/02791072.2023.2272832
Kvam, T.-M., Uthaug, M. V., Andersen, K. A. A., Refsum, B. B., Tunstad, P. A., Stewart, L. H., Jacobsen, H. B., & Grønnerød, C. (2023). Epidemiology of classic psychedelic substances: results from a Norwegian internet convenience sample. Frontiers in Psychiatry, 14. https://doi.org/10.3389/fpsyt.2023.1287196
Cruz, L., Bienemann, B., Palhano-Fontes, F., Tófoli, L. F., Araújo, D. B., & Mograbi, D. C. (2023). A quantitative textual analysis of the subjective effects of ayahuasca in naïve users with and without depression. Scientific Reports, 13(1), 19635. https://doi.org/10.1038/s41598-023-44193-5
Thornton, N. L. R., Black, W., Bognar, A., Dagge, D., Gitau, T., Hua, B., Joks, G., King, J., Lord, A., Scott, E. M., Callander, J. S., Ting, S., & Liu, D. (2023). Establishing an esketamine clinic in Australia: Practical recommendations and clinical guidance from an expert panel. Asia-Pacific Psychiatry, 15(4), e12550. https://doi.org/10.1111/appy.12550
Sugiarto, E., Leung, R., & Yuen, J. (2023). Pharmacists’ Perspectives on Psilocybin in Canada. JAPhA Practice Innovations. Advance online publication. https://doi.org/10.1016/j.japhpi.2023.100003
Oliveira-Maia, A. J., Morrens, J., Rive, B., Godinov, Y., Cabrieto, J., Perualila, N., Barbreau, S., & Mulhern-Haughey, S. (2023). ICEBERG study: an indirect adjusted comparison estimating the long-term benefit of esketamine nasal spray when compared with routine treatment of treatment-resistant depression in general psychiatry. Frontiers in Psychiatry, 14, 1250980. https://doi.org/10.3389/fpsyt.2023.1250980
Stocker, K., Hartmann, M., Ley, L., Becker, A. M., Holze, F., & Liechti, M. E. (2023). The revival of the psychedelic experience scale: Revealing its extended-mystical, visual, and distressing experiential spectrum with LSD and psilocybin studies. Journal of Psychopharmacology. Advance online publication. https://doi.org/10.1177/02698811231199112
Simonsson, O., Goldberg, S. B., Chambers, R., Osika, W., Simonsson, C., & Hendricks, P. S. (2023). Psychedelic use and psychiatric risks. Psychopharmacology. Advance online publication. https://doi.org/10.1007/s00213-023-06478-5
Korman, B. A. (2023). The Rising Use of LSD among Business Managers. Substance Use & Misuse, 59(2), 159-166. https://doi.org/10.1080/10826084.2023.2267105
Shams, S., Pratt, A. R., Li, S., & Isenbarger, T. (2023). The Evolving Role of History in the Past, Present, and Future of Psychedelic Patenting. History of Pharmacy and Pharmaceuticals, 65(1), 117-130. https://doi.org/10.3368/hopp.65.1.117
Johansen, L., Liknaitzky, P., Nedeljkovic, M., & Murray, G. (2023). How psychedelic-assisted therapy works for depression: expert views and practical implications from an exploratory Delphi study. Frontiers in Psychiatry, 14, 1265910. https://doi.org/10.3389/fpsyt.2023.1265910
Elias, S., Spivak, S., Alverez, A., Gili Olivares, A., Ferrol, M., & Keenan, J. P. (2023). Self-perception and self-recognition while looking in the mirror on psilocybin. Journal of Psychedelic Studies, 7(2), 129-134. https://doi.org/10.1556/2054.2023.00251
Engel, L., Barratt, M., Ferris, J., Puljevic, C., & Winstock, A. (2023). Mescaline, Peyote and San Pedro: Is sustainability important for cacti consumers? Journal of Psychedelic Studies, 7(2), 135-142. https://doi.org/10.1556/2054.2023.00252
Bremler, R., Katati, N., Shergill, P., Erritzoe, D., & Carhart-Harris, R. L. (2023). Case analysis of long-term negative psychological responses to psychedelics. Scientific Reports, 13(1), 15998. https://doi.org/10.1038/s41598-023-41145-x
Garel, N., Drury, J., Lévesque, J. T., Goyette, N., Lehmann, A., Looper, K., Erritzoe, D., Dames, S., Turecki, G., Rej, S., Richard-Devantoy, S., & Greenway, K. T. (2023). The Montreal model: an integrative biomedical-psychedelic approach to ketamine for severe treatment-resistant depression. Frontiers in Psychiatry, 14, 1268832. https://doi.org/10.3389/fpsyt.2023.1268832
Barnett, B. S., Arakelian, M., Beebe, D., Ontko, J., Riegal, C., Siu, W. O., Weleff, J., & Pope, H. G. (2023). American Psychiatrists’ Opinions About Classic Hallucinogens and Their Potential Therapeutic Applications: A 7-Year Follow-Up Survey. Psychedelic Medicine. Advance online publication. https://doi.org/10.1089/psymed.2023.0036
La Torre, J. T., Mahammadli, M., Faber, S. C., Greenway, K. T., & Williams, M. T. (2023). Expert Opinion on Psychedelic-Assisted Psychotherapy for People with Psychopathological Psychotic Experiences and Psychotic Disorders. International Journal of Mental Health and Addiction. Advance online publication. https://doi.org/10.1007/s11469-023-01149-0
Manson, E., Ryding, E., Taylor, W., Peekeekoot, G., Gloeckler, S. G., Allard, P., Johnny, C., Greenway, K. T., & Dames, S. (2023). Indigenous Voices in Psychedelic Therapy: Experiential Learnings from a Community-Based Group Psychedelic Therapy Program. Journal of Psychoactive Drugs, 55(5), 539-548. https://doi.org/10.1080/02791072.2023.2258120
Yonezawa, K., Tani, H., Nakajima, S., & Uchida, H. (2023). Development of the Japanese version of the 30‐item Mystical Experience Questionnaire. Neuropsychopharmacology Reports. Advance online publication. https://doi.org/10.1002/npr2.12377
Eckernäs, E., Koomen, J., Timmermann, C., Carhart‐Harris, R., Röshammar, D., & Ashton, M. (2023). Optimized infusion rates for N,N‐dimethyltryptamine to achieve a target psychedelic intensity based on a modeling and simulation framework. CPT Pharmacometrics & Systems Pharmacology, 12(10), 1398-1410. https://doi.org/10.1002/psp4.13037
Loizaga-Velder, A., Giovannetti, C., Gomez, R. C., Valenzuela, T. E. C., Jaime, G. R. O., Agin-Liebes, G., Marcus, O., & Rush, B. (2023). Therapeutic Effects of Ceremonial Ayahuasca Use for Methamphetamine Use Disorders and Other Mental Health Challenges: Case Studies in an Indigenous Community in Sonora, Mexico. Journal of Psychoactive Drugs, 55(5), 549-557. https://doi.org/10.1080/02791072.2023.2255182
Flynn, L. T., & Gao, W.-J. (2023). DNA methylation and the opposing NMDAR dysfunction in schizophrenia and major depression disorders: a converging model for the therapeutic effects of psychedelic compounds in the treatment of psychiatric illness. Molecular Psychiatry, 1-15. https://doi.org/10.1038/s41380-023-02235-4
Arkfeld, D. G., Alexopoulos, C., & Gonzales, S. A. B. (2023). Potential Benefits of Psilocybin for Lupus Pain: A Case Report. Current Rheumatology Reviews, 20(1), 97-99. https://doi.org/10.2174/1573397119666230904150750
Davis, A. K., Xin, Y., Sepeda, N., & Averill, L. A. (2023). Open-label study of consecutive ibogaine and 5-MeO-DMT assisted-therapy for trauma-exposed male Special Operations Forces Veterans: prospective data from a clinical program in Mexico. The American Journal of Drug and Alcohol Abuse, 49(5), 587-596. https://doi.org/10.1080/00952990.2023.2220874
Herrmann, Z., Levin, A. W., Cole, S. P., Slabaugh, S., Barnett, B., Penn, A., Jain, R., Raison, C., Rajanna, B., & Jain, S. (2023). Psychedelic Use Among Psychiatric Medication Prescribers: Effects on Well-Being, Depression, Anxiety, and Associations with Patterns of Use, Reported Harms, and Transformative Mental States. Psychedelic Medicine, 1(3), 139-149. https://doi.org/10.1089/psymed.2023.0030
Dubus, Z., Grandgeorge, E., & Verroust, V. (2023). History of the administration of psychedelics in France. Frontiers in Psychology, 14, 1131565. https://doi.org/10.3389/fpsyg.2023.1131565
Aday, J. S., Barnett, B. S., Grossman, D., Murnane, K. S., Nichols, C. D., & Hendricks, P. S. (2023). Psychedelic Commercialization: A Wide-Spanning Overview of the Emerging Psychedelic Industry. Psychedelic Medicine, 1(3), 150-165. https://doi.org/10.1089/psymed.2023.0013
Ramaekers, J. G., Mallaroni, P., Kloft, L., Reckweg, J. T., Toennes, S. W., van Oorsouw, K., & Mason, N. L. (2023). Altered State of Consciousness and Mental Imagery as a Function of N, N-dimethyltryptamine Concentration in Ritualistic Ayahuasca Users. Journal of Cognitive Neuroscience, 35(9), 1382-1393. https://doi.org/10.1162/jocn_a_02003
Kunstler, B. E., Smith, L., Langmead, C. J., Goodwin, D. M., Wright, B., & Hatty, M. A. (2023). “We don’t want to run before we walk”: the attitudes of Australian stakeholders towards using psychedelics for mental health conditions. Public Health Research & Practice, 33(3). https://doi.org/10.17061/phrp3332321
Kovacevich, A., Weleff, J., Claytor, B., & Barnett, B. S. (2023). Three Cases of Reported Improvement in Microsmia and Anosmia Following Naturalistic Use of Psilocybin and LSD. Journal of Psychoactive Drugs, 55(5), 672-679. https://doi.org/10.1080/02791072.2023.2253538
Feng, R., Ching, T. H. W., Bartlett, A. C., La Torre, J. T., & Williams, M. T. (2023). Healing Words: Effects of Psychoeducation on Likelihood to Seek and Refer Psychedelic-Assisted Psychotherapy Among BIPOC Individuals. Journal of Psychoactive Drugs, ahead-of-print, 1-13. https://doi.org/10.1080/02791072.2023.2253535
Rush, B., Marcus, O., García, S., Loizaga-Velder, A., Spitalier, A., & Mendive, F. (2023). Ayahuasca Treatment Outcome Project (ATOP): One Year Results from Takiwasi Center and Implications for Psychedelic Science. Journal of Studies on Alcohol and Drugs. https://doi.org/10.15288/jsad.23-00005
Zeifman, R. J., Kettner, H., Pagni, B. A., Mallard, A., Roberts, D. E., Erritzoe, D., Ross, S., & Carhart-Harris, R. L. (2023). Co-use of MDMA with psilocybin/LSD may buffer against challenging experiences and enhance positive experiences. Scientific Reports, 13(1), 13645. https://doi.org/10.1038/s41598-023-40856-5
Dougherty, R. F., Clarke, P., Atli, M., Kuc, J., Schlosser, D., Dunlop, B. W., Hellerstein, D. J., Aaronson, S. T., Zisook, S., Young, A. H., Carhart-Harris, R., Goodwin, G. M., & Ryslik, G. A. (2023). Psilocybin therapy for treatment resistant depression: prediction of clinical outcome by natural language processing. Psychopharmacology, 1-9. https://doi.org/10.1007/s00213-023-06432-5
Palamar, J. J., Rutherford, C., Le, A., & Keyes, K. M. (2023). Seasonal Variation of Use of Common Psychedelics and Party Drugs Among Nightclub/Festival Attendees in New York City. Journal of Psychoactive Drugs, ahead-of-print, 1-8. https://doi.org/10.1080/02791072.2023.2240322
Cavarra, M., Mason, N. L., Kuypers, K. P. C., Bonnelle, V., Smith, W. J., Feilding, A., Kryskow, P., & Ramaekers, J. G. (2023). Potential analgesic effects of psychedelics on select chronic pain conditions: A survey study. European Journal of Pain, 28(1), 153-165. https://doi.org/10.1002/ejp.2171
Gramling, R., Bennett, E., Curtis, K., Richards, W., Rizzo, D. M., Arnoldy, F., Hegg, L., Porter, J., Honstein, H., Pratt, S., Tarbi, E., Reblin, M., Thambi, P., Agrawal, M. (2023). Developing a Direct Observation Measure of Therapeutic Connection in Psilocybin-Assisted Therapy: A Feasibility Study. Journal of Palliative Medicine, 26(12), 1702-1708. https://doi.org/10.1089/jpm.2023.0189
Falkenberg, I., Bitsch, F., Liu, W., Matsingos, A., Noor, L., Vogelbacher, C., Yildiz, C., & Kircher, T. (2023). The effects of esketamine and treatment expectation in acute major depressive disorder (Expect): study protocol for a pharmacological fMRI study using a balanced placebo design. Trials, 24(1), 514. https://doi.org/10.1186/s13063-023-07556-x
Downey, A. E., Boyd, M., Chaphekar, A. V., Woolley, J., & Raymond‐Flesch, M. (2023). “But the reality is it’s happening”: A qualitative study of eating disorder providers about psilocybin‐assisted psychotherapy. International Journal of Eating Disorders, 56(11), 2142-2148. https://doi.org/10.1002/eat.24041
Kim, A., & Suzuki, J. (2023). Addiction specialists’ attitudes toward psychedelics: A National Survey. American Journal on Addictions, 32(6), 606-609. https://doi.org/10.1111/ajad.13461
Boehnke, K. F., Cox, K., Weston, C., Herberholz, M., Glynos, N., Kolbman, N., Fields, C. W., Barron, J., & Kruger, D. J. (2023). Slouching towards engagement: interactions between people using psychedelics naturalistically and their healthcare providers. Frontiers in Psychiatry, 14. https://doi.org/10.3389/fpsyt.2023.1224551
Teeple, A., Zhdanava, M., Pilon, D., Caron-Lapointe, G., Lefebvre, P., & Joshi, K. (2023). Access and real-world use patterns of esketamine nasal spray among patients with treatment-resistant depression covered by private or public insurance. Current Medical Research and Opinion, 39(8), 1167-1174. https://doi.org/10.1080/03007995.2023.2239045
Abrams, S. K., Rabinovitch, B. S., Zafar, R., Aziz, A. S., Cherup, N. P., McMillan, D. W., Nielson, J. L., & Lewis, E. C. (2023). Persons With Spinal Cord Injury Report Peripherally Dominant Serotonin-Like Syndrome After Use of Serotonergic Psychedelics. Neurotrauma Reports, 4(1), 543-550. https://doi.org/10.1089/neur.2023.0022
Korman, B. A. (2023). On the mushrooming reports of “quiet quitting”: Employees’ lifetime psilocybin use predicts their overtime hours worked. Journal of Psychoactive Drugs, ahead-of-print(ahead-of-print), 1-10. https://doi.org/10.1080/02791072.2023.2242358
Glynos, N. G., Kruger, D. J., Kolbman, N., Boehnke, K., & Lucas, P. (2023). The Relationship Between Naturalistic Psychedelic Use and Clinical Care in Canada. Journal of Psychoactive Drugs, 55(5), 660-671. https://doi.org/10.1080/02791072.2023.2242353
Szigeti, B., Nutt, D., Carhart-Harris, R., & Erritzoe, D. (2023). The difference between ‘placebo group’ and ‘placebo control’: a case study in psychedelic microdosing. Scientific Reports, 13(1), 12107. https://doi.org/10.1038/s41598-023-34938-7
Husain, M. I., Blumberger, D. M., Castle, D. J., Ledwos, N., Fellows, E., Jones, B. D. M., … & Mulsant, B. H. (2023). Psilocybin for treatment-resistant depression without psychedelic effects: study protocol for a 4-week, double-blind, proof-of-concept randomised controlled trial. BJPsych Open, 9(4), e134. https://doi.org/10.1192/bjo.2023.535
Lawrence, D. W., DiBattista, A. P., & Timmermann, C. (2023). N, N-Dimethyltryptamine (DMT)-Occasioned Familiarity and the Sense of Familiarity Questionnaire (SOF-Q). Journal of Psychoactive Drugs, ahead-of-print(ahead-of-print), 1-13. https://doi.org/10.1080/02791072.2023.2230568
Godes, M., Lucas, J., & Vermetten, E. (2023). Perceived key change phenomena of MDMA-assisted psychotherapy for the treatment of severe PTSD: an interpretative phenomenological analysis of clinical integration sessions. Frontiers in Psychiatry, 14, 957824. https://doi.org/10.3389/fpsyt.2023.957824
Modlin, N. L., Stubley, J., Maggio, C., & Rucker, J. J. (2023). On Redescribing the Indescribable: Trauma, Psychoanalysis and Psychedelic Therapy. British Journal of Psychotherapy, 39(3), 551-572. https://doi.org/10.1111/bjp.12852
Haug, N. A., Wadekar, R., Barry, R., & Sottile, J. (2023). Risk for Ecstasy Use Disorder and Other Substance Use Among International Users of Recreational Ecstasy/Molly/MDMA. Journal of Psychoactive Drugs, ahead-of-print(ahead-of-print), 1-10. https://doi.org/10.1080/02791072.2023.2227960
Blond, B. N., & Schindler, E. A. D. (2023). Case report: Psychedelic-induced seizures captured by intracranial electrocorticography. Frontiers in Neurology, 14, 1214969. https://doi.org/10.3389/fneur.2023.1214969
Li, I., Fong, R., Hagen, M., & Tabaac, B. (2023). Medical student attitudes and perceptions of psychedelic-assisted therapies. Frontiers in Psychiatry, 14, 1190507. https://doi.org/10.3389/fpsyt.2023.1190507
Kruger, D. J., Barron, J., Herberholz, M., & Boehnke, K. F. (2023). Preferences and Support for Psychedelic Policies and Practices Among Those Using Psychedelics. Journal of Psychoactive Drugs, 55(5), 650-659. https://doi.org/10.1080/02791072.2023.2228784
Weiss, B., Wingert, A., Erritzoe, D., & Campbell, W. K. (2023). Prevalence and therapeutic impact of adverse life event reexperiencing under ceremonial ayahuasca. Scientific Reports, 13(1), 9438. https://doi.org/10.1038/s41598-023-36184-3
Gukasyan, N., Griffiths, R. R., Yaden, D. B., Antoine, D. G., & Nayak, S. M. (2023). Attenuation of psilocybin mushroom effects during and after SSRI/SNRI antidepressant use. Journal of Psychopharmacology, 37(7), 707-716. https://doi.org/10.1177/02698811231179910
Keyes, K. M., & Patrick, M. E. (2023). Hallucinogen use among young adults ages 19–30 in the United States: Changes from 2018 to 2021. Addiction, 118(12), 2449-2454. https://doi.org/10.1111/add.16259
Agin-Liebes, G., Nielson, E. M., Zingman, M., Kim, K., Haas, A., Owens, L. T., … & Bogenschutz, M. (2023). Reports of Self-Compassion and Affect Regulation in Psilocybin-Assisted Therapy for Alcohol Use Disorder: An Interpretive Phenomenological Analysis. Psychology of Addictive Behaviors, 1-15. https://doi.org/10.1037/adb0000935
Weiss, B., Ginige, I., Shannon, L., Giribaldi, B., Murphy-Beiner, A., Murphy, R., … & Erritzoe, D. (2023). Personality change in a trial of psilocybin therapy v. escitalopram treatment for depression. Psychological Medicine, 1-15. https://doi.org/10.1017/s0033291723001514
Yavorsky, C., Ballard, E., Opler, M., Sedway, J., Targum, S. D., & Lenderking, W. (2023). Recommendations for selection and adaptation of rating scales for clinical studies of rapid-acting antidepressants. Frontiers in Psychiatry, 14, 1135828. https://doi.org/10.3389/fpsyt.2023.1135828
Lake, S., & Lucas, P. (2023). The Canadian Psychedelic Survey: Characteristics, Patterns of Use, and Access in a Large Sample of People Who Use Psychedelic Drugs. Psychedelic Medicine, 1(2), 98-110. https://doi.org/10.1089/psymed.2023.0002
Pleet, M. M., White, J., Zamaria, J. A., & Yehuda, R. (2023). Reducing the Harms of Nonclinical Psychedelics Use Through a Peer-Support Telephone Helpline. Psychedelic Medicine, 1(2), 69-73. https://doi.org/10.1089/psymed.2022.0017
Jacobs, E. (2023). Transformative experience and informed consent to psychedelic-assisted psychotherapy. Frontiers in Psychology, 14, 1108333. https://doi.org/10.3389/fpsyg.2023.1108333
Breeksema, J. J., Niemeijer, A., Kuin, B., Veraart, J., Vermetten, E., Kamphuis, J., … Schoevers, R. (2023). Phenomenology and therapeutic potential of patient experiences during oral esketamine treatment for treatment-resistant depression: an interpretative phenomenological study. Psychopharmacology, 240(7), 1547-1560. https://doi.org/10.1007/s00213-023-06388-6
Majdinasab, E., Datta, P., Krutsch, K., Baker, T., & Hale, T. W. (2023). Pharmacokinetics of Ketamine Transfer Into Human Milk. Journal of Clinical Psychopharmacology, 43(5), 407-410. https://doi.org/10.1097/jcp.0000000000001711
Makunts, T., Dahill, D., Jerome, L., de Boer, A., & Abagyan, R. (2023). Concomitant medications associated with ischemic, hypertensive, and arrhythmic events in MDMA users in FDA adverse event reporting system. Frontiers in Psychiatry, 14, 1149766. https://doi.org/10.3389/fpsyt.2023.1149766
Hietamies, T. M., McInnes, L. A., Klise, A. J., Worley, M. J., Qian, J. J., Williams, L. M., … Levine, S. P. (2023). The effects of ketamine on symptoms of depression and anxiety in real-world care settings: A retrospective controlled analysis. Journal of Affective Disorders, 335, 484-492. https://doi.org/10.1016/j.jad.2023.04.141
Davis, O. (2023). Henri Michaux’s program for the psychedelic humanities. Frontiers in Psychology, 14, 1152896. https://doi.org/10.3389/fpsyg.2023.1152896
Zhdanava, M., Teeple, A., Pilon, D., Shah, A., Caron-Lapointe, G., & Joshi, K. (2023). Esketamine nasal spray for major depressive disorder with acute suicidal ideation or behavior: description of treatment access, utilization, and claims-based outcomes in the United States. Journal of Medical Economics, 26(1), 691-700. https://doi.org/10.1080/13696998.2023.2208993
Spriggs, M. J., Murphy-Beiner, A., Murphy, R., Bornemann, J., Thurgur, H., & Schlag, A. K. (2023). ARC: a framework for access, reciprocity and conduct in psychedelic therapies. Frontiers in Psychology, 14, 1119115. https://doi.org/10.3389/fpsyg.2023.1119115
Palamar, J. J. (2023). Tusi: a new ketamine concoction complicating the drug landscape. The American Journal of Drug and Alcohol Abuse, 49(5), 546-550. https://doi.org/10.1080/00952990.2023.2207716
Romero, O. G. (2023). Cognitive liberty and the psychedelic humanities. Frontiers in Psychology, 14, 1128996. https://doi.org/10.3389/fpsyg.2023.1128996
Davis, A. K., Levin, A. W., Nagib, P. B., Armstrong, S. B., & Lancelotta, R. L. (2023). Study protocol of an open-label proof-of-concept trial examining the safety and clinical efficacy of psilocybin-assisted therapy for veterans with PTSD. BMJ Open, 13(5), e068884. https://doi.org/10.1136/bmjopen-2022-068884
Zeifman, R. J., Wagner, A. C., Monson, C. M., & Carhart-Harris, R. L. (2023). How does psilocybin therapy work? An exploration of experiential avoidance as a putative mechanism of change. Journal of Affective Disorders, 334, 100-112. https://doi.org/10.1016/j.jad.2023.04.105
Lewis, B. R., Byrne, K., Hendrick, J., Garland, E. L., Thielking, P., & Beck, A. (2023). Group format psychedelic-assisted therapy interventions: Observations and impressions from the HOPE trial. Journal of Psychedelic Studies, 7(1), 1-11. https://doi.org/10.1556/2054.2022.00222
Ching, T. H. W., Grazioplene, R., Bohner, C., Kichuk, S. A., DePalmer, G., D’Amico, E., … Kelmendi, B. (2023). Safety, tolerability, and clinical and neural effects of single-dose psilocybin in obsessive–compulsive disorder: protocol for a randomized, double-blind, placebo-controlled, non-crossover trial. Frontiers in Psychiatry, 14, 1178529. https://doi.org/10.3389/fpsyt.2023.1178529
Weiss, B., Erritzoe, D., Giribaldi, B., Nutt, D. J., & Carhart-Harris, R. L. (2023). A critical evaluation of QIDS-SR-16 using data from a trial of psilocybin therapy versus escitalopram treatment for depression. Journal of Psychopharmacology, 37(7), 717-732. https://doi.org/10.1177/02698811231167848
Kruger, D. J., Enghoff, O., Herberholz, M., Barron, J., & Boehnke, K. F. (2023). “How Do I Learn More About this?”: Utilization and Trust of Psychedelic Information Sources Among People Naturalistically Using Psychedelics. Journal of Psychoactive Drugs, 55(5), 631-639. https://doi.org/10.1080/02791072.2023.2201263
Sjöstedt-Hughes, P. (2023). On the need for metaphysics in psychedelic therapy and research. Frontiers in Psychology, 14, 1128589. https://doi.org/10.3389/fpsyg.2023.1128589
Feduccia, A., Agin-Liebes, G., Price, C. M., Grinsell, N., Paradise, S., & Rabin, D. M. (2023). The need for establishing best practices and gold standards in psychedelic medicine. Journal of Affective Disorders, 332, 47–54. https://doi.org/10.1016/j.jad.2023.03.083
Evans, J. (2023). ‘More evolved than you’: Evolutionary spirituality as a cultural frame for psychedelic experiences. Frontiers in Psychology, 14, 1103847. https://doi.org/10.3389/fpsyg.2023.1103847
Rosenblat, J. D., Leon-Carlyle, M., Ali, S., Husain, M. I., & McIntyre, R. S. (2023). Antidepressant Effects of Psilocybin in the Absence of Psychedelic Effects. American Journal of Psychiatry, 180(5), 395-396. https://doi.org/10.1176/appi.ajp.20220835
Brett, J., Knock, E., Korthuis, P. T., Liknaitzky, P., Murnane, K. S., Nicholas, C. R., … Stauffer, C. S. (2023). Exploring psilocybin-assisted psychotherapy in the treatment of methamphetamine use disorder. Frontiers in Psychiatry, 14, 1123424. https://doi.org/10.3389/fpsyt.2023.1123424
Kopra, E. I., Ferris, J. A., Winstock, A. R., Kuypers, K. P., Young, A. H., & Rucker, J. J. (2023). Investigation of self-treatment with lysergic acid diethylamide and psilocybin mushrooms: Findings from the Global Drug Survey 2020. Journal of Psychopharmacology, 37(7), 733-748. https://doi.org/10.1177/02698811231158245
Kinderlehrer, D. A. (2023). The Effectiveness of Microdosed Psilocybin in the Treatment of Neuropsychiatric Lyme Disease: A Case Study. International Medical Case Reports Journal, 16, 109-115. https://doi.org/10.2147/imcrj.s395342
Kňažek, F., Horák, M., Ocetková, T., Somerlíková, K., Bláhová, B., Plevková, M., … Kočárová, R. (2023). Typology of Users of Psychedelics and Alike Psychoactive Substances in Czechia: Results of the National Online Survey. Journal of Psychoactive Drugs, 55(5), 601-611. https://doi.org/10.1080/02791072.2023.2177908
Grimmer, H. J., Tangen, J. M., Freydenzon, A., & Laukkonen, R. E. (2023). The illusion of insight: detailed warnings reduce but do not prevent false “Aha!” moments. Cognition & Emotion, 37(2), 329-338. https://doi.org/10.1080/02699931.2023.2187352
Lewis, C. R., Tafur, J., Spencer, S., Green, J. M., Harrison, C., Kelmendi, B., … Cahn, B. R. (2023). Pilot study suggests DNA methylation of the glucocorticoid receptor gene (NR3C1) is associated with MDMA-assisted therapy treatment response for severe PTSD. Frontiers in Psychiatry, 14, 959590. https://doi.org/10.3389/fpsyt.2023.959590
Mathai, D. S., Nayak, S. M., Yaden, D. B., & Garcia-Romeu, A. (2023). Reconsidering “dissociation” as a predictor of antidepressant efficacy for esketamine. Psychopharmacology, 240(4), 827-836. https://doi.org/10.1007/s00213-023-06324-8
Perkins, D., Ruffell, S. G. D., Day, K., Rubiano, D. P., & Sarris, J. (2023). Psychotherapeutic and neurobiological processes associated with ayahuasca: A proposed model and implications for therapeutic use. Frontiers in Neuroscience, 16, 879221. https://doi.org/10.3389/fnins.2022.879221
Modlin, N. L., Miller, T. M., Rucker, J. J., Kirlic, N., Lennard-Jones, M., Schlosser, D., … Aaronson, S. T. (2023). Optimizing outcomes in psilocybin therapy: Considerations in participant evaluation and preparation. Journal of Affective Disorders, 326, 18-25. https://doi.org/10.1016/j.jad.2023.01.077
Singh, B., Vande Voort, J. L., Riva-Posse, P., Pazdernik, V. M., Frye, M. A., & Tye, S. J. (2023). Ketamine-Associated Change in Anhedonia and mTOR Expression in Treatment-Resistant Depression. Biological Psychiatry, 93(12), e65-e68. https://doi.org/10.1016/j.biopsych.2022.10.007
Gukasyan, N., & Narayan, S. K. (2023). Menstrual Changes and Reversal of Amenorrhea Induced by Classic Psychedelics: A Case Series. Journal of Psychoactive Drugs, ahead-of-print(ahead-of-print), 1-6. https://doi.org/10.1080/02791072.2022.2157350
Correll, C. U., Solmi, M., Cortese, S., Fava, M., Højlund, M., Kraemer, H. C., … Kane, J. M. (2023). The future of psychopharmacology: a critical appraisal of ongoing phase 2/3 trials, and of some current trends aiming to de‐risk trial programmes of novel agents. World Psychiatry, 22(1), 48-74. https://doi.org/10.1002/wps.21056
Forstmann, M., Kettner, H. S., Sagioglou, C., Irvine, A., Gandy, S., Carhart-Harris, R. L., & Luke, D. (2023). Among psychedelic-experienced users, only past use of psilocybin reliably predicts nature relatedness. Journal of Psychopharmacology, 37(1), 93-106. https://doi.org/10.1177/02698811221146356
van Vugt, A. S., Zijlmans, J., Lindauer, R., & van Dam, L. (2023). MDMA-assisted psychotherapy with adolescents suffering from PTSD: Do or don’t? a qualitative study with youth, parents, and clinicians. Drug Science Policy and Law, 9. https://doi.org/10.1177/20503245231198477
Brandt, J. (2023). A roadmap for psychedelic pharmacy in Canada: A proposed policy and operations approach for controlled access to select psychedelics for treatment of mental illness. Drug Science Policy and Law, 9, 20503245231170340. https://doi.org/10.1177/20503245231170340
Tsang, V. W. L., Tao, B., Dames, S., Walsh, Z., & Kryskow, P. (2023). Safety and tolerability of intramuscular and sublingual ketamine for psychiatric treatment in the Roots To Thrive ketamine-assisted therapy program: a retrospective chart review. Therapeutic Advances in Psychopharmacology, 13. https://doi.org/10.1177/20451253231171512
D’Arienzo, A., & Samorini, G. (2023). Italian psychedelic therapies of the past century: An historical overview. Drug Science Policy and Law, 9, 20503245231179687. https://doi.org/10.1177/20503245231179687
Rajwani, K. (2023). The “Third” Eye: Ethics of Video Recording in the Context of Psychedelic-Assisted Therapy. Canadian Journal of Bioethics, 6(3-4), 8. https://doi.org/10.7202/1108000ar
Holoyda, B. J. (2022). Malpractice and Other Civil Liability in Psychedelic Psychiatry. Psychiatric Services, 74(1), 92-95. https://doi.org/10.1176/appi.ps.20220528
Hadar, A., David, J., Shalit, N., Roseman, L., Gross, R., Sessa, B., & Lev-Ran, S. (2023). The Psychedelic Renaissance in Clinical Research: A Bibliometric Analysis of Three Decades of Human Studies with Psychedelics. Journal of Psychoactive Drugs, 55(1), 1-10. https://doi.org/10.1080/02791072.2021.2022254
Andersson, M., Persson, M., & Kjellgren, A. (2023). Psychoactive substances as a last resort—a qualitative study of self-treatment of migraine and cluster headaches. Harm Reduction Journal, 14(1), 60. https://doi.org/10.1186/s12954-017-0186-6
Baggott, M. J. (2023). Learning about STP – A Forgotten Psychedelic from the Summer of Love. History of Pharmacy and Pharmaceuticals, 65(1), 93–116. https://doi.org/10.3368/hopp.65.1.93
Pagán, A. F., Lex, C., Soares, J. C., & Meyer, T. D. (2023). Medical students’ attitudes and beliefs toward psilocybin: Does terminology and personal experience with psychedelics matter? Psychedelic Medicine, 1(3), 130–138. https://doi.org/10.1089/psymed.2023.0022
Price, R. B., Wallace, M. L., Mathew, S. J., & Howland, R. H. (2023). One-Year Outcomes Following Intravenous Ketamine Plus Digital Training Among Patients with Treatment-Resistant Depression: A Secondary Analysis of a Randomized Clinical Trial. JAMA network open, 6(5), e2312434. https://doi.org/10.1001/jamanetworkopen.2023.12434
Sandbrink, J. D., Johnson, K., Gill, M., Yaden, D. B., Savulescu, J., Hannikainen, I. R., & Earp, B. D. (in press). Strong bipartisan support for controlled psilocybin use as treatment or enhancement in a representative sample of US Americans: need for caution in public policy persists. AJOB Neuroscience, in press.
Doll, Agnieszka. (in press). Making ‘Medical”: How Psychedelics Are Becoming Legal in Canada. Dalhousie Law Journal, in press.
Batievsky, D., Weiner, M., Kaplan, S. B., Thase, M. E., Maglione, D. N., & Vidot, D. C. (2023). Ketamine-assisted psychotherapy treatment of chronic pain and comorbid depression: a pilot study of two approaches. Frontiers in pain research (Lausanne, Switzerland), 4, 1127863. https://doi.org/10.3389/fpain.2023.1127863
Rieser, N. M., Gubser, L. P., Moujaes, F., Duerler, P., Lewis, C. R., Michels, L., Vollenweider, F. X., & Preller, K. H. (2023). Psilocybin-induced changes in cerebral blood flow are associated with acute and baseline inter-individual differences. Scientific reports, 13(1), 17475. https://doi.org/10.1038/s41598-023-44153-z
Li, A., Liu, H., Lei, X., He, Y., Wu, Q., Yan, Y., Zhou, X., Tian, X., Peng, Y., Huang, S., Li, K., Wang, M., Sun, Y., Yan, H., Zhang, C., He, S., Han, R., Wang, X., & Liu, B. (2023). Hierarchical fluctuation shapes a dynamic flow linked to states of consciousness. Nature communications, 14(1), 3238. https://doi.org/10.1038/s41467-023-38972-x
Moujaes, F., Rieser, N. M., Phillips, C., de Matos, N. M. P., Brügger, M., Dürler, P., Smigielski, L., Stämpfli, P., Seifritz, E., Vollenweider, F. X., Anticevic, A., & Preller, K. H. (2023). Comparing Neural Correlates of Consciousness: From Psychedelics to Hypnosis and Meditation. Biological psychiatry. Cognitive neuroscience and neuroimaging, S2451-9022(23)00174-X. Advance online publication. https://doi.org/10.1016/j.bpsc.2023.07.003
Ruffini, G., Damiani, G., Lozano-Soldevilla, D., Deco, N., Rosas, F. E., Kiani, N. A., Ponce-Alvarez, A., Kringelbach, M. L., Carhart-Harris, R., & Deco, G. (2023). LSD-induced increase of Ising temperature and algorithmic complexity of brain dynamics. PLoS Computational Biology, 19(2), e1010811. https://doi.org/10.1371/journal.pcbi.1010811
Luppi, A. I., Vohryzek, J., Kringelbach, M. L., Mediano, P. A. M., Craig, M. M., Adapa, R., Carhart-Harris, R. L., Roseman, L., Pappas, I., Peattie, A. R. D., Manktelow, A. E., Sahakian, B. J., Finoia, P., Williams, G. B., Allanson, J., Pickard, J. D., Menon, D. K., Atasoy, S., & Stamatakis, E. A. (2023). Distributed harmonic patterns of structure-function dependence orchestrate human consciousness. Communications Biology, 6(1), 117. https://doi.org/10.1038/s42003-023-04474-1
Herzog, R., Mediano, P. A. M., Rosas, F. E., Lodder, P., Carhart-Harris, R., Perl, Y. S., Tagliazucchi, E., & Cofre, R. (2023). A whole-brain model of the neural entropy increase elicited by psychedelic drugs. Scientific reports, 13(1), 6244. https://doi.org/10.1038/s41598-023-32649-7
Luppi, A. I., Hansen, J. Y., Adapa, R., Carhart-Harris, R. L., Roseman, L., Timmermann, C., Golkowski, D., Ranft, A., Ilg, R., Jordan, D., Bonhomme, V., Vanhaudenhuyse, A., Demertzi, A., Jaquet, O., Bahri, M. A., Alnagger, N. L. N., Cardone, P., Peattie, A. R. D., Manktelow, A. E., de Araujo, D. B., … Stamatakis, E. A. (2023). In vivo mapping of pharmacologically induced functional reorganization onto the human brain’s neurotransmitter landscape. Science advances, 9(24), eadf8332. https://doi.org/10.1126/sciadv.adf8332
Bedford, P., Hauke, D. J., Wang, Z., Roth, V., Nagy-Huber, M., Holze, F., Ley, L., Vizeli, P., Liechti, M. E., Borgwardt, S., Müller, F., & Diaconescu, A. O. (2023). The effect of lysergic acid diethylamide (LSD) on whole-brain functional and effective connectivity. Neuropsychopharmacology, 48(8), 1175–1183. https://doi.org/10.1038/s41386-023-01574-8
Tolle, H. M., Farah, J. C., Mallaroni, P., Mason, N. L., Ramaekers, J. G., & Amico, E. (2023). The Unique Neural Signature of Your Trip: Functional Connectome Fingerprints of Subjective Psilocybin Experience. Network Neuroscience, 1-54. https://doi.org/10.1162/netn_a_00349
Delli Pizzi, S., Chiacchiaretta, P., Sestieri, C., Ferretti, A., Tullo, M. G., Della Penna, S., Martinotti, G., Onofrj, M., Roseman, L., Timmermann, C., Nutt, D. J., Carhart-Harris, R. L., & Sensi, S. L. (2023). LSD-induced changes in the functional connectivity of distinct thalamic nuclei. NeuroImage, 283, 120414. https://doi.org/10.1016/j.neuroimage.2023.120414